We hypothesize that age‑dependent mitochondrial dysfunction drives epigenetic silencing of mismatch repair (MMR) genes via ROS‑mediated inhibition of TET enzymes, thereby initiating a feed‑forward loop of microsatellite instability, senescence‑associated secretory phenotype, and field cancerization that explains the nonlinear CRC risk rise after age 59.

In aged colon epithelium, cumulative oxidative stress elevates mitochondrial ROS, which oxidizes Fe²⁺ cofactors required for Ten‑Eleven Translocation (TET) dioxygenases. Impaired TET activity reduces 5‑hydroxymethylcytosine at CpG shores of MLH1, MSH2 and MSH6 promoters, favoring DNMT1‑mediated methylation and stable silencing [https://pmc.ncbi.nlm.nih.gov/articles/PMC12689014/]. Loss of MMR creates a mutator phenotype preferentially at microsatellite repeats embedded in stem‑cell niche regulators (e.g., LGR5, ASCL2), generating insertion‑deletion mutants that impair niche signaling and promote stem‑cell exhaustion.

We'll see that defective niche signaling triggers a retrograde mitochondrial stress response: reduced ATP and increased ROS activate the ATM‑p53‑p21 axis, pushing epithelial cells into a senescent state. Senescent fibroblasts, already expanded by age‑linked inflammaging, secrete IL‑6, IL‑8 and PGE₂ (SASP) that further inhibit TET enzymes via NF‑κB‑driven DNMT up‑regulation, closing the loop [https://pmc.ncbi.nlm.nih.gov/articles/PMC12689014/]. The resulting epigenetic field—widespread methylation of MMR and niche genes—creates a permissive landscape for independent adenoma initiation, accounting for the observed increase in synchronous lesions after age 59 [https://www.gutnliver.org/journal/view.html?doi=10.5009%2Fgnl15334].

Key predictions:

1. Organoids derived from colon biopsies of donors >60 years will show higher mitochondrial ROS, lower TET activity, and increased methylation of MMR promoters compared with <40‑year‑old controls.
2. Pharmacological scavenging of mitochondrial ROS (MitoTEMPO) or supplementation with NAD⁺ precursors (nicotinamide riboside) will restore TET activity, decrease MLH1 methylation, and reduce SASP factor secretion in aged organoids.
3. Inducing TET overexpression via CRISPR‑a in aged fibroblasts will attenuate SASP production and limit methylation spread in co‑cultured epithelial organoids.
4. In vivo, treating aged mice with MitoTEMPO will lower colonic MLH1 methylation, decrease microsatellite instability markers, and reduce tumor multiplicity in the AOM/DSS model.

Falsifiability: If mitochondrial ROS levels don't correlate with TET inhibition or MMR methylation in aged human tissue, or if antioxidant/NAD⁺ interventions fail to reverse methylation or SASP in organoid models, the hypothesis would be refuted. Likewise, demonstrating that MMR loss occurs without preceding mitochondrial ROS elevation would challenge the proposed causal order.

By linking mitochondrial redox state to epigenetic drift and niche collapse, this model offers a testable bridge between the nonlinear age risk curve, epigenetic aging markers, and field cancerization, and suggests mitochondrial‑targeted nutraceuticals can't fully replace surveillance but may delay onset in older adults.